Stallion India Fluorochemicals Limited – Rights Issue 2026
Stallion India Fluorochemicals Limited is a specialised manufacturer and distributor of refrigerants and speciality gases catering to industries such as semiconductors, automotive, electronics, pharmaceuticals, healthcare, fire safety, and aerosol manufacturing. The company focuses on Hydrofluorocarbons (HFCs), Hydrofluoroolefins (HFOs), and blended refrigerant formulations designed for industrial efficiency and energy optimisation.
With four processing and manufacturing facilities across Maharashtra, Rajasthan, and Haryana, the company has built a strong infrastructure for debulking, blending, bottling, and large-scale gas handling operations. The upcoming Rights Issue is aimed at capacity expansion and strengthening its speciality gases portfolio, positioning the company for long-term growth in high-demand industrial segments.
Current Market Price: Rs. 165.37
Rights Issue Offer Price: Rs. 99 per share
Last Updated: 14 February 2026, 6.00 AM
👉 GMP | Reviews | Subscription | Allotment
👉 Chanakya Grey Market Intelligence – 8 PM Edition | News Crux |
👉 Power Calls | Breakout Stocks | Coffee Can Portfolio |
Rights Issue Details
Issue Open – 20 February 2026
Issue Close – 27 February 2026
| Particulars | Details |
|---|---|
| Security Name | Stallion India Fluorochemicals Limited |
| Issue Size (Shares) | 3,67,60,483 |
| Issue Size (Amount) | Rs. 363.93 Crores |
| Issue Price | Rs. 99 per share |
| Face Value | Rs. 10 per share |
| Entitlement Ratio | 19 : 41 |
| Listing At | BSE, NSE |
| Terms of Payment | Full amount payable on application |
Rights Issue Timetable
| Event | Date |
|---|---|
| Last Date to Buy Shares | 09-Feb-2026 |
| Record Date | 11-Feb-2026 |
| Credit of Rights Entitlements | 19-Feb-2026 |
| Bid/Offer Opens On | 20-Feb-2026 |
| Renunciation of Rights Entitlements | 23-Feb-2026 |
| Bid/Offer Closes On | 27-Feb-2026 |
| Deemed Date of Allotment | 02-Mar-2026 |
| Credit Date | 04-Mar-2026 |
| Listing Date | 05-Mar-2026 |
Objects of the Rights Issue
The Company intends to utilise the Net Proceeds from the Issue towards the following objectives:
| Issue Objects | Est Amt (Rs. Cr.) |
|---|---|
| Setting up new unit including land acquisition, civil works, machinery, EPC, commissioning, training and technology transfer | 320.10 |
| General corporate purposes | 7.83 |
Financial Snapshot
| Period Ended | 31-Mar-2025 | 31-Mar-2024 |
|---|---|---|
| Total Assets | 333.67 | 200.01 |
| Total Income | 379.47 | 236.23 |
| Profit After Tax | 32.33 | 15.47 |
| Amount in Rs. Crore |
(Amount in Rs. Crore)
Revenue and profitability have shown strong growth, with income rising significantly and PAT more than doubling YoY, indicating improving operational efficiency and strong demand for speciality gases.
Company Contact Information
Stallion India Fluorochemicals Limited
2A, Knox Plaza,
Mindspace, Off Link Road, Malad West
Mumbai – 400064
Phone: 02243510000
Email: sf@stallion.in
Website: stallion.in
Registrar to the Rights Issue
Bigshare Services Pvt. Ltd.
Phone: +91-22-6263 8200
Email: rightsissue@bigshareonline.com
Website: bigshareonline.com
Lead Manager of the Rights Issue
(To be announced)
Stallion India Fluorochemicals Limited – Rights Issue Review
(By Paresh Gordhandas, CA & Research Analyst)
Stallion India Fluorochemicals is raising Rs. 363.93 crore through its Rights Issue priced at Rs. 99 per share, which is available at a significant discount to the current market price of around Rs. 165.37. The proceeds are largely earmarked for setting up a new manufacturing unit, highlighting the company’s aggressive expansion strategy in speciality gases and refrigerants — segments benefiting from increasing industrial and environmental demand.
Financial performance shows strong momentum, with revenue growth and PAT expansion reflecting improving scale and margins. The capital infusion is expected to strengthen capacity, enhance product mix, and support long-term growth in fluorochemicals.
Chanakya View:
Given the strong growth trajectory, expansion-driven fundraising, and discounted pricing, existing shareholders may consider participation from a medium-to-long-term perspective, while new investors should evaluate execution risks associated with capacity expansion.
Quicklinks
